Otsuka's novel TB drug filed in Japan
This article was originally published in Scrip
Otsuka Pharmaceutical has filed the second approval application worldwide for delamanid (OPC-67683), its novel oral molecule for multidrug-resistant tuberculosis (MDR-TB).
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.